Quick Take
- Narration: Will Damron delivers a controlled, journalistic read that matches Carreyrou’s investigative voice, clear and propulsive without sensationalizing material that is already extraordinary.
- Themes: Silicon Valley hubris and investor credulity, the human cost of medical fraud, investigative journalism under legal pressure
- Mood: Tense and methodical, with the gathering momentum of a well-constructed exposé
- Verdict: One of the most compelling true-crime business narratives in audio form, Damron’s narration gives the investigation the weight it earned.
I was halfway through my morning commute when I started Bad Blood, intending to listen for twenty minutes and switch to something lighter. I did not switch. I missed my usual coffee stop. I sat in the parking lot outside my office for eleven more minutes because I needed to know what happened to one specific whistleblower. That is not a sequence of events I had anticipated from a book about laboratory equipment and blood testing.
John Carreyrou’s account of Elizabeth Holmes and Theranos, the Silicon Valley startup that claimed to revolutionize diagnostics with a finger-prick blood test and turned out to have falsified nearly everything, is one of those rare pieces of investigative journalism that reads as inevitably as a thriller while being rigorously documented. Carreyrou, the Wall Street Journal reporter who broke the story, spent years gathering sources willing to speak on record despite Theranos’s aggressive legal team. That effort is visible on every page.
Our Take on Bad Blood
The New York Times Book Review called it "chilling" and noted it "reads like a thriller," which is accurate but slightly undersells it. What Carreyrou has done is more specific: he has reconstructed the internal experience of a company built on fraud from the inside out, using sources who were inside when the fraud was ongoing and often frightened to speak. The result is not a portrait of Holmes from the outside, distant and speculative, but a detailed account of what it felt like to be an employee, an investor, or a patient whose test results were wrong.
Holmes herself is rendered with genuine complexity. Carreyrou does not reduce her to a simple villain. He tracks how her vision, which may initially have been sincere, hardened into deception as the technical reality failed to catch up with the promises she had already made. The relationship with Sunny Balwani, her partner and Theranos COO, is examined with the same specificity, the ways they reinforced each other’s certainties and silenced dissent together.
Why Listen to Bad Blood
Will Damron’s narration is matched precisely to Carreyrou’s prose style. The writing is journalistic, precise and declarative, building its case methodically, and Damron reads it with the controlled momentum of a good news story: not dramatic, but focused. The restraint is appropriate. The material does not need theatrical delivery; the facts are already extraordinary. One reviewer with professional knowledge of the diagnostics industry described Carreyrou’s reporting as accurate to her domain knowledge, which is the highest possible endorsement for a lay journalist working in specialized terrain.
At just under twelve hours, Bad Blood never drags. Carreyrou’s structure is clean, he moves between corporate timeline, source perspectives, and investigative obstacles without losing the thread. Damron handles the multiple perspectives without confusion; the large cast of Theranos employees, investors, and board members remains distinguishable throughout.
What to Watch For in Bad Blood
This edition includes an afterword with updated information on Holmes’s legal situation. Worth noting: events have continued to develop since publication (Holmes was convicted in January 2022 and began serving her sentence later that year), so some listeners may find the afterword slightly incomplete relative to current events. That is not a flaw in the book; it is the nature of ongoing legal proceedings. The core narrative is complete and fully documented.
One reviewer uses a Ringling Brothers analogy that is accurate: Theranos was a company that "strapped a horn on a goat and marketed it as a real thing." What makes Bad Blood more disturbing than most unicorn collapse stories is that the goat in question was administering medical diagnoses to real patients, some of whom made healthcare decisions based on erroneous results.
Who Should Listen to Bad Blood
Anyone interested in Silicon Valley’s failure modes, in the mechanics of sophisticated fraud, or in the specific vulnerability of investor culture to charismatic vision will find this essential listening. It is also, perhaps unexpectedly, a book about investigative journalism and its costs: Carreyrou and his sources faced serious legal pressure, and that pressure is part of the story.
If you have already seen the Hulu docuseries The Dropout or the HBO documentary The Inventor, you will know the broad outlines of the Holmes story. Bad Blood fills in what documentaries necessarily compress, and Carreyrou’s sourcing gives it an authority that dramatizations cannot replicate.
Frequently Asked Questions
Does Bad Blood cover Holmes’s trial and conviction, or does it end before that?
The book covers Carreyrou’s investigation and the immediate aftermath, the SEC charges and early legal proceedings. An afterword adds some updated context, but the trial and conviction (January 2022) postdate the main text. The core investigation is fully told.
How does Will Damron handle the large cast of Theranos employees and investors?
Damron reads with controlled clarity that keeps the large cast distinguishable without theatrical differentiation. His approach suits the journalistic register of Carreyrou’s prose, methodical and focused rather than performative.
Is prior knowledge of the Theranos story necessary, or does the book orient newcomers?
Carreyrou orientates listeners fully, no prior knowledge required. In fact, some readers find the book more effective coming in cold, since the gradual revelation of how the fraud operated mirrors the experience of the investors and employees who were deceived in real time.
Is this book fair to Elizabeth Holmes, or does it function as a takedown?
Multiple reviewers note that Carreyrou’s treatment is more complex than a simple takedown. He tracks how Holmes’s initial vision may have been sincere and how it hardened into fraud as technical reality failed to match promises. The book is damning but not reductive.
